Advanced search
Publication Cover
Acta Oncologica Volume 58, 2019 - Issue 8
Journal homepage
3,045
Views
28
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: TREATMENT AND OUTCOMES

A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer

Stig E. AndersenClinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark; Correspondence[email protected]
View further author information
,
Ida B. AndersenClinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark; View further author information
,
Benny V. JensenDepartment of Oncology, Herlev University Hospital, Herlev, Denmark; View further author information
,
Per PfeifferDepartment of Oncology, Odense University Hospital, Odense, Denmark; View further author information
,
Takayo OtaDepartment of Medical Oncology, Izumi City General Hospital, Izumi, OsakaJapan; View further author information
&
Jim S. LarsenDepartment of Oncology, Zealand University Hospital, Roskilde, DenmarkView further author information
Pages 1149-1157 | Received 19 Nov 2018, Accepted 29 Mar 2019, Published online: 19 Apr 2019

Citations (28)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Lucjan Wyrwicz, Julien Taieb, Timothy Price, Jean-Baptise Bachet, Meinolf Karthaus, Loïck Vidot, Bénédicte Chevallier, Timo Reisländer, Lena Weiss & Volker Heinemann. (2023) Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. Colorectal Cancer 12:3.
Read now
Yvonne Andersson, Else Marit Inderberg, Gunnar Kvalheim, Theodor Malmer Herud, Olav Engebraaten, Kjersti Flatmark, Svein Dueland & Øystein Fodstad. (2020) Immune stimulatory effect of anti-EpCAM immunotoxin – improved overall survival of metastatic colorectal cancer patients. Acta Oncologica 59:4, pages 404-409.
Read now

Articles from other publishers (26)

Yugandhar Kothapalli, Ransom A. Jones, Chung K. Chu & Uma S. Singh. (2024) Synthesis of Fluorinated Nucleosides/Nucleotides and Their Antiviral Properties. Molecules 29:10, pages 2390.
Crossref
Juraj Prejac, Tomislav Omrčen, Jasna Radić, Eduard Vrdoljak, Ana Fröbe & Stjepko Pleština. (2024) Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis. Oncology 102:3, pages 217-227.
Crossref
Gerlinde Maria Michl, Florian M. Vogt, Andreas Nouriani, Roland Ladurner, Marcus Kremer, Timo Reisländer & Marlies Michl. (2024) Long-Term Progression-Free Survival of a Pre-Treated Patient with Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil. Chemotherapy 69:1, pages 27-34.
Crossref
D. Marques, A.L. Costa, A. Mansinho, A. Quintela, E. Pratas, J. Brito-da-Silva, J. Cruz, J. Félix, J. Rodrigues, M. Mota, A.R. Teixeira, S. Dâmaso, S. Pinheiro, V. Andreozzi, L. Costa & A.G. Barros. (2023) The REWRITE Study – REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer. Clinical Oncology 35:10, pages 665-672.
Crossref
Hendrik Kröning, Thomas Göhler, Thomas Decker, Marc Grundeis, Georgi Kojouharoff, Jörg Lipke, Dieter Semsek, Enno Moorahrend, Annette Sauer, Harald‐Robert Bruch, Rüdiger Liersch, Arnd Nusch, Ursula Vehling‐Kaiser, Manfred Welslau, Ralf Grunewald, Hanns‐Detlev Harich, Marcel Stephany, Jens Uhlig, Rebecca de Buhr, Melanie Frank, Cathrin Hogrefe, Norbert Marschner, Karin Potthoff, Frank Hartmann, Timo Reisländer & Ingo Schwaner. (2023) Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real‐world data from the noninterventional TACTIC study in Germany . International Journal of Cancer 153:6, pages 1227-1240.
Crossref
Ioannis A. Voutsadakis. (2023) A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series. Current Oncology 30:6, pages 5227-5239.
Crossref
Gerald W. PragerJulien TaiebMarwan FakihFortunato CiardielloEric Van CutsemElena ElezFelipe M. CruzLucjan WyrwiczDaniil StroyakovskiyZsuzsanna PápaiPierre-Guillaume PoureauGabor LipositsChiara CremoliniIgor BondarenkoDominik P. ModestKarim A. Benhadji, Nadia AmellalCatherine LegerLoïck VidotJosep Tabernero. (2023) Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. New England Journal of Medicine 388:18, pages 1657-1667.
Crossref
Ana Paula Ornellas S. Victorino, Fernando Meton, Luciana Mardegan, Juliana Festa, Diogo N. Piranda & Kelly Borges Araujo. (2023) Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology 14:4, pages 101477.
Crossref
Anna Koumarianou, Anastasios Ntavatzikos, David Symeonidis, Christos Vallilas, Maria Giannakakou, Georgios Papaxoinis, Spyridon Xynogalos, Ioannis Boukovinas, Stamatina Demiri, Katerina Kampoli, Georgios Oikonomopoulos, Epaminontas Samantas, Eleni Res, Nikolaos Androulakis, Georgia Vourli, Ioannis Souglakos & Michalis Karamouzis. (2023) RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer. Biomedicines 11:5, pages 1267.
Crossref
Hai-chuan Su, Jie Min, Yang Song, Li-li Liu, Lin-na Liu & He-long Zhang. (2023) A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions. Cancer Chemotherapy and Pharmacology 91:2, pages 167-177.
Crossref
Qizheng Li, Xia Zhang, Buqun Fan, Yudie Yang, Xiaonan Cui, Jie Zhang, Kaiteng Jiang, Chunxia Zhang & Bin Zhang. (2022) Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report. Frontiers in Oncology 12.
Crossref
Daniel Sur, Cristina Lungulescu, Ștefan Spînu, Alecsandra Gorzo, Elena-Adriana Dumitrescu, Dan Ionut Gheonea & Cristian-Virgil Lungulescu. (2022) Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis. Frontiers in Pharmacology 13.
Crossref
Tuo Chen, Zhen Wang, Junbo Zhong, Lijun Zhang, Haopeng Zhang, Dayong Zhang, Xiaofeng Xu, Xianfei Zhong, Jing Wang & Hai Li. (2022) Secoisolariciresinol diglucoside induces pyroptosis by activating caspase‐1 to cleave GSDMD in colorectal cancer cells. Drug Development Research 83:5, pages 1152-1166.
Crossref
Nyan Y. Khin, Madhawa De Silva, Stephen Clarke, Nick Pavlakis, Chris M. Rogan, Kevin Ho-Shon & Rodney J. Lane. (2022) Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases. Annals of Surgical Oncology 29:6, pages 3387-3389.
Crossref
A Jalali, G Gard, S Banks, C Dunn, HL Wong, R Wong, M Lee, L Gately, M Loft, JD Shapiro, S Kosmider, J Tie, S Ananda, J M Yeung, R Jennens, B Lee, J McKendrick, L Lim, A Khattak & P Gibbs. (2022) Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. Current Problems in Cancer 46:2, pages 100793.
Crossref
Cheng-Jiang Liu, Ting Hu, Ping Shao, Wu-Yang Chu, Yu Cao & Feng Zhang. (2021) TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer. Gastroenterology Research and Practice 2021, pages 1-14.
Crossref
Ioannis A. Voutsadakis. (2021) Biomarkers of Trifluridine-Tipiracil Efficacy. Journal of Clinical Medicine 10:23, pages 5568.
Crossref
Pilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, Paula Jiménez-Fonseca, Carles Pericay, Federico Longo-Muñoz, Carmen Reyna-Fortes, Guillem Argilés-Martínez, Beatriz González-Astorga, María José Gómez-Reina, Ana Ruiz-Casado, Nuria Rodríguez-Salas, Rafael López-López, Alberto Carmona-Bayonas, Verónica Conde-Herrero & Enrique Aranda. (2021) Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers 13:18, pages 4514.
Crossref
Sakti Chakrabarti, Grant Wintheiser, Sri Harsha Tella, Carolyn Oxencis & Amit Mahipal. (2021) TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. Pharmacology & Therapeutics 224, pages 107823.
Crossref
Ana Fernández Montes, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Francisca Vázquez Rivera, Nieves Martinez Lago, Marta Covela Rúa, Antía Cousillas Castiñeiras, Paula Gonzalez Villarroel, Juan De la Cámara Gómez, José Carlos Méndez Méndez, Carmen Carriles Fernández, Manuel Sanchez Cánovas & Teresa Garcia García. (2021) Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Scientific Reports 11:1.
Crossref
Daniel Tong, Lei Wang, Jeewaka Mendis & Sharadah Essapen. (2021) Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience. Current Oncology 28:3, pages 2260-2269.
Crossref
Per Pfeiffer & Camilla Qvortrup. 2021. Multidisciplinary Treatment of Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 187 202 .
Per Pfeiffer & Camilla Qvortrup. 2021. Multidisciplinary Treatment of Colorectal Cancer. Multidisciplinary Treatment of Colorectal Cancer 159 161 .
Elsa N. Garza Treviño, Paulina Delgado-Gonzalez, Carlos I. Valencia Salgado & Jorge L. Ortega Garcia. (2020) Pericytes Relationship with Cancer Stem Cells in the Colon. Current Tissue Microenvironment Reports 1:4, pages 187-198.
Crossref
Thomas Walter, Neil S. Hawkins, Richard F. Pollock, Fabien Colaone, Suki Shergill & Paul J. Ross. (2020) Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology 146:10, pages 2575-2587.
Crossref
Per Pfeiffer, Mette Yilmaz, Sören Möller, Daniela Zitnjak, Merete Krogh, Lone Nørgård Petersen, Laurids Østergaard Poulsen, Stine Braendegaard Winther, Karina Gravgaard Thomsen & Camilla Qvortrup. (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. The Lancet Oncology 21:3, pages 412-420.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.